Humanin
Also known as: HN, Humanin peptide, HN-24
5 notable studies · 8 references
TLDR
Humanin is a mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, metabolic regulation, cardiovascular biology, and aging, with extensive preclinical evidence but limited evidence from controlled human administration.
Research Supports
- Studied for neuroprotective activity against Alzheimer's-disease-related cellular insults
- Investigated for interactions with apoptosis-regulating proteins and cell survival
- Studied for roles in insulin sensitivity and metabolic regulation
- Investigated in cardiovascular and vascular stress models
- Examined for associations with aging, healthspan, and longevity across species
Observations Reported in Research
- Hashimoto et al., 2001: protected cultured neurons from familial Alzheimer's genes and amyloid-beta toxicity
- Muzumdar et al., 2009: central administration improved insulin sensitivity via hypothalamic STAT3 in rodents
- Circulating Humanin concentrations were reported to decline with age in humans and mice
- Yen et al., 2020: overexpression extended C. elegans lifespan; HNG improved metabolic healthspan in mice
- Offspring of centenarians had higher circulating Humanin levels than age-matched controls
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Mitochondrial-derived peptide (MDP); endogenous cytoprotective micropeptide associated with the mitochondrial 16S rRNA (MT-RNR2) region
Humanin is a small mitochondrial-derived peptide first identified through research into neuronal protection from Alzheimer’s-disease-related cellular stress. Researchers now study Humanin in neuroprotection, apoptosis, metabolic regulation, insulin sensitivity, cardiovascular biology, inflammation, cellular stress resistance, and aging. Humanin occurs naturally in humans, but most evidence for administering Humanin or its more potent analogues remains preclinical.
What Is Humanin?
Humanin is a naturally occurring micropeptide first reported in 2001 after researchers screened genetic material from the brain of a patient with Alzheimer’s disease for factors capable of protecting neurons from disease-related cellular injury. The resulting peptide was named “Humanin.” Humanin is generally described as a mitochondrial-derived peptide associated with a short open reading frame within the mitochondrial 16S ribosomal RNA region. It is commonly described as a 24-amino-acid peptide when translated in the cytoplasm. Its discovery helped contribute to a broader change in how researchers think about mitochondria. Beyond producing cellular energy, mitochondria can encode small signaling peptides that participate in communication, metabolism, stress responses, and cell survival. Humanin has subsequently been detected in tissues and circulation and investigated across a much wider range of biological processes. A substantial amount of experimental research uses modified Humanin analogues—particularly S14G-Humanin, often called HNG—that can be considerably more potent than native Humanin.
What Are Researchers Studying?
Neuroprotection and Alzheimer’s disease
Humanin was discovered because of its ability to protect cultured neuronal cells against several Alzheimer’s-disease-related insults, including amyloid-beta toxicity and cellular injury associated with familial Alzheimer’s disease mutations. Subsequent research has investigated Humanin and Humanin analogues in models of amyloid toxicity, oxidative stress, neuroinflammation, synaptic dysfunction, and cognitive impairment. Most intervention evidence in this area remains preclinical.
Cell survival and apoptosis
Humanin is widely studied as a cytoprotective peptide. Researchers have investigated its interactions with proteins controlling programmed cell death, including members of the BCL-2 protein family. Humanin has been reported to interfere with pro-apoptotic signaling under certain cellular stress conditions. This cytoprotective activity helps explain why Humanin research extends well beyond the nervous system.
Insulin sensitivity and metabolic regulation
Researchers have investigated Humanin as a potential link between mitochondrial signaling, aging, insulin resistance, and metabolic disease. Animal experiments have reported improved insulin sensitivity and glucose regulation following Humanin or Humanin-analogue administration. Human studies have also examined circulating Humanin concentrations in relation to age and metabolic health. These findings have not established Humanin as a treatment for diabetes or insulin resistance in humans.
Cardiovascular and vascular biology
Humanin has been investigated in models of endothelial dysfunction, atherosclerosis, ischemia-reperfusion injury, and other forms of cardiovascular stress. Researchers are particularly interested in its relationships with oxidative stress, inflammation, mitochondrial dysfunction, and cell survival. Most therapeutic intervention evidence in this area comes from experimental models rather than established human treatments.
Aging and longevity biology
Humanin levels and signaling have been investigated in relation to aging across several species. Research has reported age-associated differences in Humanin concentrations and has examined whether manipulating Humanin signaling affects metabolic health, inflammation, stress resistance, healthspan, or lifespan in experimental organisms. Human observations involving long-lived individuals are particularly interesting but do not establish that increasing Humanin extends human lifespan.
Mitochondrial stress signaling
Humanin is part of the broader family of mitochondrial-derived peptides that researchers believe participate in communication between mitochondrial status and the rest of the cell. Its biological effects appear to involve both intracellular interactions and extracellular signaling pathways, making Humanin an important model for studying how mitochondria communicate cellular stress.
How Does It Work?
Humanin appears to operate through several signaling mechanisms rather than one single pathway. Inside cells, Humanin has been reported to interact with proteins involved in apoptosis, including the pro-apoptotic protein BAX and other BCL-2-family proteins. These interactions may interfere with portions of the cellular death program under particular stress conditions. Humanin can also act extracellularly. Research has described signaling involving a receptor complex containing CNTFR, WSX-1, and gp130, which can activate downstream pathways including JAK/STAT signaling. Other work has implicated formyl peptide receptors. Metabolic experiments have connected Humanin signaling with hypothalamic STAT3 activity and regulation of peripheral insulin action. The relative importance of these mechanisms appears to depend on tissue, experimental conditions, and whether researchers are studying native Humanin or a modified analogue. Humanin is therefore better understood as a multifunctional stress-response and signaling peptide than as a compound acting through one simple receptor.
What Does the Research Show?
Human research
Human research has primarily examined naturally occurring Humanin rather than administering Humanin as an experimental treatment. Humanin has been detected in human circulation and tissues, and researchers have examined circulating concentrations in relation to age, metabolic health, cardiovascular disease, neurodegenerative disease, and longevity. A 2009 study reported that circulating Humanin concentrations declined with age in humans and mice as part of a broader investigation into Humanin and insulin sensitivity. Later work examining longevity biology found comparatively higher circulating Humanin levels among offspring of centenarians than age-matched controls. Other studies have reported differing Humanin patterns in disease populations, and the relationship between circulating Humanin concentrations, aging, and disease remains incompletely understood. These studies demonstrate that Humanin is biologically relevant in humans, but observational associations do not establish that administering Humanin or a Humanin analogue produces clinical benefit.
Animal research
Animal research has examined Humanin across metabolic, neurological, cardiovascular, inflammatory, and aging-related models. Experiments have reported effects involving insulin sensitivity, glucose regulation, amyloid-related neurotoxicity, cardiovascular injury, inflammatory signaling, and cellular stress resistance. Research using the potent Humanin analogue HNG has also investigated metabolic health and aging-related outcomes in mice. A 2020 study examining Humanin across several species reported that Humanin overexpression increased lifespan in C. elegans and that treatment of middle-aged mice with HNG improved several metabolic healthspan measures and reduced inflammatory markers.
In-vitro research
Cellular research forms the foundation of the Humanin literature. Humanin was originally identified through experiments showing protection of neuronal cells from several Alzheimer’s-disease-related insults. Subsequent cell studies have investigated Humanin in amyloid-beta toxicity, oxidative stress, apoptosis, mitochondrial dysfunction, inflammatory signaling, and metabolic stress. Researchers have also used cellular experiments to identify important structural features of Humanin and investigate interactions with apoptosis-related proteins and cell-surface signaling systems.
Notable Studies
A Rescue Factor Abolishing Neuronal Cell Death by a Wide Spectrum of Familial Alzheimer’s Disease Genes and Aβ
in-vitroThis foundational study identified Humanin through functional screening of a cDNA library derived from Alzheimer’s disease brain tissue. Researchers found that Humanin protected cultured neuronal cells from death caused by several familial Alzheimer’s-disease-associated genes and amyloid-beta-related toxicity. The work established Humanin as a previously unknown cytoprotective peptide and provided the starting point for subsequent research into mitochondrial-derived peptides and neuroprotection.
Limitations: The principal experiments were performed in cellular models. Protection of cultured neurons from experimentally induced toxicity does not demonstrate prevention or treatment of Alzheimer’s disease in humans. The study also preceded much of the later work clarifying Humanin’s mitochondrial origin, signaling mechanisms, physiological concentrations, and broader biological functions.
View publication →Evidence for In Vivo Production of Humanin Peptide, a Neuroprotective Factor Against Alzheimer’s Disease-Related Insults
animalAfter Humanin had been identified through cellular screening, researchers investigated whether the peptide could actually be produced in vivo. Using Humanin-directed antibodies, the investigators detected Humanin immunoreactivity in mouse tissues and reported Humanin immunoreactivity in Alzheimer’s disease brain tissue. The study provided early evidence that Humanin was more than an artificial product of the original experimental screening system and could be biologically produced.
Limitations: Detection of Humanin immunoreactivity does not establish its physiological concentration, complete tissue distribution, causal role in disease, or therapeutic effect. The work also relied on early detection methods developed when Humanin biology was still being established.
View publication →Humanin: A Novel Central Regulator of Peripheral Insulin Action
animalResearchers investigated whether Humanin influences insulin sensitivity and whether Humanin biology changes with age. In rodent experiments, central Humanin administration improved insulin sensitivity through signaling involving hypothalamic STAT3. Peripheral administration of potent Humanin derivatives also produced insulin-sensitizing effects, and a Humanin analogue lowered blood glucose in a diabetic rat model. The researchers additionally reported that Humanin levels declined with age in several rodent tissues and that circulating Humanin concentrations decreased with age in humans and mice.
Limitations: The intervention experiments were conducted primarily in rodents and included potent Humanin derivatives rather than exclusively native Humanin. The human component examined circulating Humanin concentrations rather than therapeutic administration. The study therefore does not establish Humanin as a treatment for insulin resistance or diabetes in humans.
View publication →The Mitochondrial Derived Peptide Humanin Is a Regulator of Lifespan and Healthspan
animalResearchers examined Humanin across species to investigate relationships with aging, lifespan, metabolic health, and longevity. Humanin overexpression increased lifespan in C. elegans through a mechanism dependent on daf-16/Foxo. In mice, Humanin-related interventions were associated with protection from stress, and treatment of middle-aged animals with the potent Humanin analogue HNG improved several metabolic healthspan measures and reduced inflammatory markers. The study also reported that Humanin levels generally declined with age across species but remained comparatively stable in the exceptionally long-lived naked mole-rat. Human offspring of centenarians had higher circulating Humanin concentrations than age-matched controls.
Limitations: The lifespan-extension experiment was performed in C. elegans, not humans. Mouse intervention experiments included the potent analogue HNG rather than demonstrating equivalent effects from native Humanin in people. Higher Humanin concentrations in offspring of centenarians represent an association and do not show that Humanin caused their families’ longevity. The study therefore does not establish Humanin as a human longevity treatment.
View publication →Role of Humanin, a Mitochondrial-Derived Peptide, in Cardiovascular Disorders
animalThis review examined evidence connecting Humanin with cardiovascular biology, including oxidative stress, endothelial function, inflammation, metabolism, and mitochondrial dysfunction. The authors discussed experimental evidence suggesting that Humanin may participate in cardiovascular stress responses and considered its potential both as a marker of mitochondrial function and as a future therapeutic research target. The review illustrates how Humanin research expanded from its original neuroprotective context into broader cardiovascular and metabolic biology.
Limitations: This publication is a review rather than a controlled intervention study. Much of the underlying therapeutic evidence comes from cellular and animal models. Proposed clinical applications therefore remain hypotheses requiring direct human testing.
View publication →What We Still Don't Know
Despite more than two decades of research, major questions about Humanin remain unresolved. Important unanswered questions include: - Whether administering Humanin provides meaningful clinical benefits in humans - Human pharmacokinetics and bioavailability following exogenous administration - Short- and long-term safety of Humanin administration - How physiological Humanin concentrations vary among tissues and individuals - Whether circulating Humanin is a useful biomarker, active signaling molecule, compensatory response, or some combination of these - Which Humanin signaling mechanisms are most important in humans - How native Humanin differs functionally from potent analogues such as HNG - Whether Humanin-related effects observed in Alzheimer’s disease models translate into meaningful human neuroprotection - Whether metabolic improvements observed in rodents translate to humans - Whether associations between Humanin and exceptional longevity are causal - How Humanin interacts with other mitochondrial-derived peptides such as MOTS-c and the SHLP family The biological evidence for Humanin is substantial, but controlled human intervention evidence remains limited.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Humanin research with you.
Get the Aminodex Humanin Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Hashimoto Y, Niikura T, Tajima H, et al. A Rescue Factor Abolishing Neuronal Cell Death by a Wide Spectrum of Familial Alzheimer’s Disease Genes and Aβ. Proceedings of the National Academy of Sciences of the United States of America. 2001;98(11):6336-6341. doi:10.1073/pnas.101133498.
- Hashimoto Y, Niikura T, Ito Y, et al. Detailed Characterization of Neuroprotection by a Rescue Factor Humanin Against Various Alzheimer’s Disease-Relevant Insults. Journal of Neuroscience. 2001;21(23):9235-9245.
- Tajima H, Niikura T, Hashimoto Y, et al. Evidence for In Vivo Production of Humanin Peptide, a Neuroprotective Factor Against Alzheimer’s Disease-Related Insults. Neuroscience Letters. 2002;324(3):227-231. doi:10.1016/S0304-3940(02)00199-4.
- Muzumdar RH, Huffman DM, Atzmon G, et al. Humanin: A Novel Central Regulator of Peripheral Insulin Action. PLoS ONE. 2009;4(7).
- Yen K, Mehta HH, Kim SJ, et al. The Mitochondrial Derived Peptide Humanin Is a Regulator of Lifespan and Healthspan. Aging. 2020;12(12):11185-11199.
- Thummasorn S, Shinlapawittayatorn K, Chattipakorn SC, Chattipakorn N. Role of Humanin, a Mitochondrial-Derived Peptide, in Cardiovascular Disorders. Archives of Cardiovascular Diseases. 2020;113(8-9):564-571. doi:10.1016/j.acvd.2020.03.020.
- Boutari C, Pappas PD, Theodoridis TD, Vavilis D. Humanin and Diabetes Mellitus: A Review of In Vitro and In Vivo Studies. World Journal of Diabetes. 2022;13(3):213-223. doi:10.4239/wjd.v13.i3.213.
- Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Peptides Derived from Small Mitochondrial Open Reading Frames: Genomic, Biological, and Therapeutic Implications. Experimental & Molecular Medicine. 2020;52:1093-1102.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.